Websites of Borstel
Research Center Borstel
Leibniz Lung Center
Visit our central website.
Here you can find out more about our research, current press releases, publications and events.
Lipidomics Forum - The focus of the conference is on microbial lipids and the role of lipids in infectious diseases.
NDI³ - scientific conference for new developments in immunology, inflammation and infection.
Run for your lungs! - Annual fundraising run by the Borstel Research Center and SV Sülfeld.
Network
Numerous partners are supporting the scientists of the Research Center Borstel in their daily work: intellectual properties (IP), technology transfer, political interests and cooperations.
Ascenion
Ascenion provides comprehensive and exclusive Intellectual Property (IP) Asset Management services to the Research Center Borstel. The range of services comprises all activities that form part of modern IP Asset Management, ranging from technology scouting and hunting to equity management and contract follow-up including prosecution and litigation.
EURICE
The Eurice GmbH offers comprehensive support for the planning and implementation of international EU-funded R&D projects providing support and consultancy for our scientists from the first project idea to the successful completion.
Forschungsportal Immunologie Hamburg
Das Forschungsportal Immunologie Hamburg fasst die Aktivitäten der beteiligten akademischen Institute, der Forschungsinstitute und mittelständischen Unternehmen zusammen, als Voraussetzung für ein erfolgreiches wissenschaftliches und wirtschaftliches Netzwerk.
helminGuard - Drug discovery on live worms
Discovery of new anthelminthic agents - Assessment of immunomodulatory side effects of drugs - Custom testing and delivery of Schistosoma mansoni worms and materials for research purposes and vaccine development
Robert Koch Institute and DZK
The Robert Koch Institute is one of the central institutions for health protection in Germany. It serves the Federal Ministry of Health as a central scientific institution in the field of biomedicine. The Institute combines risk research with political advice. Its most important tasks include protection against infectious diseases and the analysis of the health situation in Germany.
Issues concerning the epidemiologiy of tuberculosis and and means of control are cooperatively developed withe the Research Center Borstel (National Reference Center for Mycobacteria) and the Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK).
„Tierversuche verstehen – Eine Informationsinitiative der Wissenschaft“
„Tierversuche verstehen“ ist eine Initiative der deutschen Wissenschaft, koordiniert von der Allianz der Wissenschaftsorganisationen. Sie informiert umfassend, aktuell und faktenbasiert über Tierversuche an öffentlich geförderten Forschungseinrichtungen. Die biomedizinische Forschung dient unmittelbar der Aufklärung grundlegender Prozesse im Organismus und der Entwicklung neuer Verfahren in der Prävention, Diagnose und Therapie von Erkrankungen beim Menschen wie Krebs, Diabetes, Aids und Alzheimer, und auch bei Tieren.
University of Lübeck, Christian-Albrechts-University of Kiel, University of Hamburg
The FZB and the universities of Schleswig-Holstein are linked by a cooperation that has been built up over decades and finds its formal expression in several cooperation agreements on research and teaching.
On the scientific level, the FZB and the universities are partners, among others, in the German Health Centers for Infection and Lung Research, in the Cluster of Excellence "Precision Medicine in Chronic Inflammation" and furthermore connected via the Liaison Group Cellular Pneumology (University of Lübeck, Prof. Cordula Stamme) and the liaison group Immune-related Lung Diseases (Prof. Dr. Xinhua Yu / Prof. Dr. Frank Petersen (FZB), Prof. Dr. Gabriela Riemekasten (Univ. Lübeck).
Cooperation with the University of Hamburg and the University Medical Center Eppendorf (UKE) has been intensified in recent years, also within the framework of the DZIF. Formally, there has been a cooperation agreement with the UKE since 2014 and a joint appointment in 2020 (W2 Diagnostic Mycobacteriology, Prof. F. Maurer). The Leibniz Science Campus InterACt (Integrative analysis of pathogen-induced compartments) is a cooperation project to strengthen networking between the Leibniz Institute of Virology (LIV) and the University of Hamburg in the field of infection and structural biology, and offers the FZB a broad basis for cooperation within the Leibniz Center for Infection.
Centre for Structural Systems Biology (CSSB)
The FZB has been an associate member of the CSSB since 2016 and participates as a guest in the CSSB directorate meetings. At CSSB, there are unique opportunities to perform structural biology studies using light and X-ray radiation sources that are unique in Europe (PETRA III, FLASH, European-XFEL). The cooperation agreement enables the use of the different facilities at CSSB within the LCI alliance. The FZB will implement a permanent liaison group at the CSSB in 2021 to be able to use the metrological possibilities in close proximity to the biological experiment.
Willkommen in der Thematischen Translationseinheit Tuberkulose TTU TB des Deutschen Zentrums für Infektionsforschung (DZIF)
Koordinator: Stefan Niemann FZB
Co-Koordinatoren: Christoph Lange (Klinische Infektiologie, FZB), Ulrich Schaible (Programmbereich Infektion, FZB), Michael Hölscher (Abteilung für Tropenmedizin, LMU)
Trotz immenser Anstrengungen zur Eindämmung der Tuberkulose (TB) weltweit, konnte die Zahl der Neuerkrankungen bisher nicht signifikant gesenkt werden. Zur Zeit kann keine erfolgversprechende Vakzine angeboten werden, Medikamente zur Behandlung der TB stehen nur sehr limitiert zur Verfügung und die Entwicklung neuer Therapeutika ist in den letzten Jahren nur sehr unzureichend vorangetrieben worden. Darüber hinaus sind Infektionswege und die Herausbildung von Resistenzen gegen die zuerst eingesetzten Therapeutika nur unzulänglich untersucht und bisher nur selten mit modernen molekularbiologischen Methoden unterstützt.
Die TTU TB des DZIF hat sich daher zum Ziel gesetzt durch den Einsatz neuer Verfahren zur Diagnostik und durch das Überprüfen der Wirksamkeit neuer Substanzen einen entscheidenden Beitrag zur Kontrolle und Bekämpfung von TB-Infektionen insbesondere der multi- bis extrem-resistenten TB zu leisten.
Am FZB sind die folgenden Teilprojekte der TTU TB lokalisiert:
- EpiMyc: TB Epidemiologie und TB Diagnostik
- MycoMouse: in vitro und in vivo Teststation
- MycoLip: Lipidom Einheit
- M/XDR-Kohorte
- Clin TB
Der Aufbau eines "International Clinical Trial Centers" steht im Focus der Zusammenarbeit mit der von Michael Hölscher (Co-Koordinator TTU TB) geleiteten Partner Site an der Ludwig-Maximilians-Universität (LMU) in München.
Kooperationen mit Wissenschaftlern der Universitäten Hannover, Münster, Saarbrücken, Tübingen und Freiburg beinhalten vor allem Studien zur Wirksamkeit neuer Therapeutika bzw. die Etablierung einer "Lab on Disc" Technologie zum einfachen Nachweis einer TB Infektion.
Ein Fact-Sheet unserer Forschungsaktivitäten können Sie hier herunterladen.
Die Infrastruktureinheit EpiMyc der TTU TB beschäftigt sich mit der Erbgut-Analyse von Tuberkulose-Erregern. Hier stehen Methoden zur Hochdurchsatz-Genotypisierung klinischer M.tuberculosis Komplex Isolate zur Verfügung:
- ABI 3500 XL Analyzer
- MiSeq Bench Sequenzer
Im Rahmen der EpiMyc ist die Forschungsgruppe Molekulare Mykobakteriologie des FZB mit zwei Teilprojekten an der TTU TB beteiligt:
- TB Epidemiologie
- TB Diagnostik
TB Epidemiologie
Im Teilgebiet TB Epidemiologie der Infrastruktur EpiMyc werden folgende Gebiete mit Hilfe neuester molekularbiologischer Methoden untersucht:
- „TB Surveillance“
- lokale TB Epidemiologie in Deutschland
- Analysen zur Ausbreitung, Evolution und Fitness von M/XDR Stämmen
- Etablierung von Genom-basierten Verfahren für Diagnostik und molekulare Epidemiologie
TB Diagnostik
In der molekularen TB Diagnostik kommen neueste molekularbiologische Methoden auf folgenden Gebieten zum Einsatz:
- Etablierung neuer diagnostischer Tests zum einfachen Nachweis von Resistenzen
- molekulare Differenzierung von klinischen Mtb Isolaten
Zusammen mit afrikanischen DZIF und CANTAM (Central Africa Network for Tuberculosis) Studienzentren werden folgende Projekte durchgeführt:
- molekularbiologische Studien zur besseren Beschreibung von Übertragungswegen der MDR/XDR-TB
- Korrelation der molekularbiologischen Daten zur Beschreibung von Übertragunswegen mit klinischen Daten
- Etablierung einer web basierten Datenbank
Ansprechpartner: Stefan Niemann (Koordinator der TTU TB)
In der Forschungsgruppe Infektionsimmunologie steht mit einem Labor der Schutzstufe 3 (gemäß Biostoffverordnung; BSL 3) ein Labor für Untersuchungen zur Pathogenese der Tuberkulose und der Evaluation neuer therapeutischer Maßnahmen bereit.
Ein Aerosol-Inhalationsmodell in der Maus bietet die Möglichkeit, antituberkulös wirksame Substanzen und immunmodulatorische Strategien im Maus-Modell auf ihre therapeutische Effizienz hin zu untersuchen bzw. weiter zu entwickeln.
Des weiteren sind verschiedene Methoden zur in vitro Analyse von Wirkstoffen etabliert.
Diese sogenannte präklinische Teststation steht Kooperationspartnern aus dem DZIF zur Verfügung.
Ansprechpartner: Christoph Hölscher
in vitro Test
Die Infrastruktur MycoMouse hält in vitro Testmodelle bereit, in denen die antimykobakterielle Aktivität von zu testenden Substanzen überprüft und bestimmt werden kann:
- MGIT „liquid culture systems“: Bestimmung von biologisch wirksamen Konzentrationen gegenüber sensitiven Mtb- bzw. MDR/XDR-Stämmen
- in vitro-Stress-System: Überprüfung der antimykobakteriellen Wirksamkeit von Substanzen unter nicht replikativen Bedingungen
- xCELLigence system (Roche): in vitro Modell zur Beobachtung und Dokumentation der Vitalfunktionen von humanen und murinen Makrophagen nach Infektion mit Mtb und anschließender Behandlung mit antimikrobiellen Substanzen (Überprüfung der Toxizität von Substanzen)
Ansprechpartner: Christoph Hölscher (Infektionsimmunologie, FZB),
Norbert Reiling (Mikrobielle Grenzflächenbiologie, FZB)
in vivo Test
Das Aerosol-Inhalationsmodell in der Maus wurde für Untersuchungen zur Pathogenese der TB- und Therapieforschung optimiert.
In der in-vivo-Teststation werden antituberkulös wirksame Substanzen und immunmodulatorische Strategien untersucht.
Von DZIF Kooperationspartnern zur Verfügung gestellte potentiell wirksame Substanzen bzw. zusammen mit DZIF Kooperationspartnern entwickelte Therapiemodelle können hier hinsichtlich therapeutischer Effizienz und möglicher Anwendbarkeit bei TB-Patienten überprüft werden.
Ansprechpartner: Christoph Hölscher (Infektionsimmunologie, FZB),
Kerstin Walter (Infektionsimmunologie, FZB)
In der Infrastruktur-Einheit MycoLip stehen mehrere Methoden zur Analyse von Glycolipiden bzw. zur Analyse eines Gesamtspektrums von Lipiden (Lipidom-Analyse) zur Verfügung: sowohl mykobakterielle Zellwandglycolipide werden hier charakterisiert als auch das Spektrum von anti- und pro-entzündlichen Lipiden, welches im infizierten Wirt, während einer mykobakteriellen Infektion freigesetzt wird. Das Ziel dieser Arbeiten ist es, zum einen Unterschiede im mykobakteriellen Glykolipidmuster den verschiedenen Virulenz- und Ausbreitungsverhalten von Mtb-Stämmen zuzuordnen und mit bestimmten Mtb-Genotypen zu korrelieren. Zum anderen erhofft man sich über die exakte Analyse des Spektrums von Lipiden im Blut eines Patienten Parameter bestimmen zu können, die einen Aufschluss über den Verlauf einer Infektion geben und somit zur besseren Beschreibung des Heilungsverlaufs unter einer TB-Therapie herangezogen werden können. Die Verkürzung eines Therapie-Protokolls anhand solcher Parameter würde einen großen Fortschritt bei der Akzeptanz einer TB-Therapie und die Vermeidung bzw. Reduzierung von gravierenden Nebenwirkungen für den Patienten bedeuten.
MycoLip stellt dieses Spektrum an Methoden zur Charakterisierung bakterieller Glykolipide und zur Spezifikation anti- und pro-entzündlicher Lipide Partnern im DZIF sowohl für präklinische als auch klinische Untersuchungen bereit.
Folgende Methoden stehen zur Verfügung:
- nasschemische Extraktion von Lipiden
- Fouriertransformation-Ionenzyklotronresonanz-Massenspektrometrie (FT ICR-MS)
- Matrix-unterstützte Laser-Desorption/Ionisations-Massenspektrometrie mit Flugzeitanalysator (MALDI TOF-MS)
- HPLC
- Kombinierte Gaschromatographie und Massenspektrometrie
- Kernspinresonanzspektroskopie (NMR)
Ansprechpartner: Ulrich Schaible (Co-Koordinator der TTU TB), Dominik Schwudke
Das Forschungszentrum Borstel als Partner des Airway Research Center North (ARCN), Mitglied des Deutschen Zentrum für Lungenforschung (DZL)
Das Forschungszentrum Borstel ist eine von 22 Partnerinstitutionen, die sich in einem durch ein internationales Gutachterkomittee begleiteten, kompetitiven Verfahren zur Mitarbeit im Deutschen Zentrum für Lungenforschung (DZL) qualifiziert haben. Das DZL stellt ein nationales Forschungsnetzwerk dar, das es Wissenschaftlern aus Medizin wie Lebenswissenschaften und klinisch tätigen Ärzten erlaubt, über die Grenzen der eigenen Institutionen und Standorte hinaus eng zusammenzuarbeiten. Ziel ist es, durch die gemeinsame Erforschung von gesundheitspolitisch besonders bedeutenden Lungenerkrankungen innovative Beiträge zur Verbesserung der Gesundheit unserer Bevölkerung sowie zur Sicherung unserer Gesundheitssysteme zu leisten.
An den Forschungsarbeiten im Rahmen des DZL sind folgende Wissenschaftlerinnen und Wissenschaftler des FZB als Principal Investigator (PI) beteiligt (in alphabetischer Reihenfolge): Katarzyna Duda, Heinz Fehrenbach, Andreas Frey, Karoline Gaede, Torsten Goldmann, Holger Heine, Otto Holst, Uta Jappe, Susanne Krauss-Etschmann, Frank Petersen, Dominik Schwudke und Michael Wegmann.
Das DZL ist eines von sechs vom Bundesministerium für Bildung und Forschung (BMBF) initiierten und geförderten nationalen Gesundheitszentren (http://www.bmbf.de/de/gesundheitszentren.php).
Struktur des DZL
Das Spektrum der DZL-Partnerinstitutionen reicht von Universitäten, Universitätsklinika und freien Kliniken bis zu außeruniversitären Instituten der Leibniz-Gemeinschaft, der Fraunhofer-Gesellschaft und der Max-Planck-Gesellschaft sowie einem Helmholtz-Zentrum. Zusätzlich wurde mit CAPNETZ ein Forschungsnetzwerk zur Verbesserung der Therapie ambulant erworbener Pneumonien als assoziierter Partner in das DZL aufgenommen. Durch die Vernetzung von Grundlagenforschung, präklinischer Forschung an Tiermodellen bis hin zur klinischen Forschung, gelingt es innovative Forschungsansätze entlang der gesamten translationalen Kette umzusetzen.
Das DZL untergliedert sich in fünf Standort-Verbünde, in denen die jeweiligen Partner eng zusammenarbeiten. Gemeinsam mit der Universitäten Kiel und Lübeck, dem UKSH und der LungenClinic Grosshansdorf bildet das FZB den Standortverbund
Die weiteren Standorte sind
Das DZL wird in seiner ersten Förderperiode (2011-15) mit insgesamt etwa 73 Mio. Euro gefördert, wovon über 5 Mio. Euro zur Etablierung von am FZB angesiedelten DZL-relevanten Infrastrukturen bzw. initiierten Forschungsprojekten zur Verfügung gestellt werden. 90% dieser Summe werden vom BMBF getragen, 10% von den jeweiligen Sitzländern der Standorte. Projektträger ist das Helmholtz-Zentrum München.
Forschungsgebiete im DZL
Ziel des DZL ist die Erforschung von Lungenerkrankungen, für welche zukünftig stark steigende Fallzahlen prognostiziert werden bzw. umfassende Behandlungsansätze fehlen.
Dementsprechend wurden folgende Handlungsfelder, in denen besonderer Forschungsbedarf (unmet medical needs) besteht, als sogenannte Disease Areas definiert:
- Asthma & Allergie
- COPD (chronisch-obstruktive Lungenerkrankung)
- Lungenkrebs
- Cystische Fibrose
- Akute Lungenverletzungen
- Lungenerkrankungen im Endstadium
- Diffuse Parenchymale Lungenerkrankungen
- Pulmonale Hypertonie
Alle Disease Areas interagieren mit den zwei, primär technologisch definierten Plattformen (Platform Biobanking, Platform Imaging), deren vielfältige Aufgaben u.a. die harmonisierte Sammlung von Biomaterialien und Bilddaten sowie das Datenmanagement umfasse
Im Airway Research Center North (ARCN) stehen insbesondere Asthma & Allergie, COPD (chronisch-obstruktive Lungenerkrankung) und Lungenkrebs im Fokus der Studien. Durch einen neuartigen, integrativen Ansatz sollen Grundlagenforschung und klinische Forschung zusammengeführt werden, um möglichst schnell Fortschritte bei Prävention, Diagnose und Therapie der erwähnten Volkskrankheiten zu erzielen. Insbesondere durch intensive Kooperationen mit anderen DZL-Standorten ist mit einem deutlichen Mehrwert sowohl auf wissenschaftlicher als auch therapeutischer Seite zu rechnen.
Dem ARCN gehören neben dem Forschungszentrum Borstel folgende Partnerinstitutionen an:
- Die Universität zu Lübeck bringt ihre Expertise im Bereich Imaging ein. Hierbei sollen insbesondere neue Bildgebungsverfahren für den Einsatz in den Atemwegen optimiert werden und in den Bereichen COPD und AA Anwendung finden.
- Die Universität Kiel ergänzt das Forschungsspektrum des ARCN um Tiermodelle des angeborenen Immunsystems, welches unter anderem für das Krankheitsgeschehen bei COPD und Asthma wie auch bei Allergien von Bedeutung ist.
- Die LungenClinic Grosshansdorf ist eine Fachklinik mit großem Einzugsbereich im Norden und Nordosten Deutschlands. Die LungenClinic beteiligt sich im Rahmen des DZL an Studien in den Bereichen COPD, LC und AA und ist zentrales Sputumlabor des DZL.
- Das Universitätsklinikum Schleswig-Holstein (Campus Kiel) trägt insbesondere im Bereich Genetik und Epigenetik zur Erforschung des Nichtkleinzelligen Lungenkarzinoms bei.
- Der Campus Lübeck des UKSH legt den Schwerpunkt auf die den Aufbau der Kollaborative Kinder-Asthma-Kohorte (KIRA), epigenetische Forschung und eine Klinische Studie zur Therapie der Cystischen Fibrose.
Die Standortkoordination des ARCN übernimmt die Geschäftsstelle an der LungenClinic Grosshansdorf. Professor K. F. Rabe (LungenClinic Grosshansdorf, CAU Kiel) ist Standortdirektor des ARCN und Mitglied des DZL-Direktoriums. Er arbeitet eng mit den Mitgliedern des ARCN Executive Boards, Prof. S. Krauss-Etschmann (FZB, CAU) und Prof. Peter König (UzL) zusammen. In der Geschäftsstelle arbeiten J. Bullwinkel als Standortkoordinator und B. Peters als Finanz- und Projektkoordinatorin.
Weitere Informationen finden Sie ebenfalls auf der Homepage des Airway Research Center North (ARCN): www.arcn.de
Mit den ambitionierten Zielen des DZL und den sich damit in den Forschungsprojekten der Disease Areas und Plattformen stellenden Aufgaben innerhalb eines großen nationalen Forschungsverbundes ergeben sich besondere Herausforderungen. Um diesen in adäquater Form begegnen zu können und die entsprechende Nachhaltigkeit bei der Verankerung der Fördermaßnahme zu erreichen, wurde ein Gutteil der Fördermittel am FZB dafür eingesetzt, notwendige Forschungsinfrastrukturen entweder auszubauen oder gar neu einzurichten. Auf Grund der außerordentlichen Bedeutung, die das FZB den Deutschen Gesundheitszentren beimisst, werden diese Infrastrukturen zusätzlich personell verstärkt oder durch Sach- bzw. Investitionsmittel der Programmbereiche unterstützt. Im Kontext der in den Programmbereichen verfolgten Ziele soll so eine möglichst optimale Einbindung der DZL-Vorhaben in die Forschungsagenda des FZB erreicht und idealerweise nachhaltige Synergien erzeugt werden.
DZL-Labor für humane Primärzell- und Gewebekulturen
Ziel des DZL-Labors für humane Primärzell- und Gewebekulturen ist es, aus resektierten humanen Lungen, bronchialen Bürstungen oder Biopsien Primärzellen oder Gewebe zu gewinnen, distinkte Zelltypen anzureichern und/oder für in-vitro bzw. ex-vivo Experimente in Kultur zu nehmen. Im Verbund mit den entsprechenden Einrichtungen der DZL-Standorte BREATH (Prof. Dr. A. Braun, Fraunhofer ITEM), CPC-M (Prof. Dr. S. Krauss-Etschmann) und TLRC (PD Dr. M. Lampe) wird so eine standort-übergreifende DZL-Infrastruktur geschaffen, die es ermöglicht, die Durchführung von für translationale Fragestellungen unerlässlichen Proof-of-Concept Experimenten an humanen Biomaterialien sicherzustellen.
Die bereits etablierten Methoden der ex-vivo-Kultur (Short Term Stimulation of Tissues [STST] , Precision Cut Lung Slices [PCLS]) sowie der murinen und humanen Air-liquid Interface (ALI)-Kultur werden im huPCL eingesetzt und weiterentwickelt. Zusätzlich werden primäre humane Zellen gewonnen (derzeit alveoläre Epithelzellen Typ II, Alveolarmakrophagen und Mastzellen), welche für Vorhaben innerhalb und außerhalb des DZL zur Verfügung stehen. Die hiermit geschaffene Möglichkeit, funktionell im humanen System zu forschen ist ein Alleinstellungsmerkmal des ARCN und Bindeglied zwischen Grundlagen- und translationaler Forschung.
Das DZL-Labor für humane Primärzell- und Gewebekulturen wurde in interdisziplinärer Zusammenarbeit der Forschungsgruppe Pathologie mit der LungenClinic Grosshansdorf und dem Programmbereich Asthma/Allergie am FZB etabliert. Es steht in enger Verbindung mit der BioMaterialBank-Nord und wird von den beiden Forschungsgruppen Pathologie und Experimentelle Pneumologie betrieben.
Materialnutzung:
Bei Anfragen zur Nutzung von Materialien richten Sie bitte einen Antrag mit genauer Beschreibung des Projektes insbesondere der hierfür benötigten Zellen oder Gewebe inklusive der Zeiträume an Prof. Dr. T. Goldmann [Pathologie, PA3, 04537-188-2310, tgoldmann@fz-borstel.de]. Verwenden Sie hierzu bitte die Nutzungsanfrage und den Proben- und Datennutzungsantrag.
Die Steuerungsgruppe der Biomaterialbank-Nord bearbeitet diesen Antrag. Grundlage ist die Geschäftsordnung der Biomaterialbank-Nord.
Download BMB Nord Proben- und Datennutzungsantrag
Leitung
- Prof. Dr. T. Goldmann (FG. Pathologie)
- Stellvertreter: Prof. Dr. H. Fehrenbach (FG Exp. Pneumologie)
Wissenschaftliche Mitarbeiter:innen
- Dr. C. Vock (FG Exp. Pneumologie)*
- Dr. S. Marwitz (FG. Pathologie)*
- M. Sc. Dörte Nitschkowski (FG Pathologie)*
Technische Mitarbeiter:innen
- B. Baron-Lühr (FG Pathologie)
- P. Prilla (FG Exp. Pneumologie)
* finanziert bzw. teilfinanziert aus DZL-Fördermitteln
Leibniz-Association
The Research Center Borstel is a member of the Leibniz-Association (WGL). Currently, the Leibniz Association is a syndication of 87 scientific, legally authorized and economically independent research institutes and service facilities in Germany and accordingly, one of the largest German scientific organizations. All of the Leibniz institutions are actively engaged in thematically defined, future oriented fields of research which are of global interest. The consequent, transparent and strictly external assessment procedure is a singular hallmark of the WGL in comparison to the other university and external university research organizations in Germany.
Leibniz-Center Infection
The Research Center Borstel, the Leibniz Institute of Virology, LIV and the Bernhard-Nocht-Institute (BNI) are mutual founding members of the Leibniz Center Infection (LCI). The three institutes are constituent members of the Leibniz Association and each has, respectively, a clear cut biological infection mission.
The Research Center Borstel is focused on bacteria induced infections of the lung, e.g. tuberculosis. The LIV is mainly working on human viral diseases, whereas the BNI devotes itself to research on tropical diseases, especially parasitic infections. Altogether, approximately 1,000 persons are employed at the three institutes, around 300 of whom are scientists.
The aim of LCI (flyer) is to advance inventive and innovative basic research concerning biological infection in the Hamburg/Schleswig Holstein region. Correlations between science and methodology are to be identified; cooperative research projects initiated and improved possibilities for the evaluation of research results are to be established.
Leibniz Graduate School "Model Systems for Infectious Diseases"
Leibniz Research Alliances
Leibniz institutions form collaborative research alliances which use inter- and transdisciplinary approaches to address current scientific and socially-relevant issues.
The alliances are designed for a period of five to 15 years and are open for collaboration with universities, other non-university research institutions and infrastructure facilities as well as research groups abroad.
The FZB is currently partner in the following networks:
- Nanosafety
- Pharmaceutical Agent and Biotechnology
- Medical Technology: Diagnosis, Monitoring and Therapy.
The Leibniz research alliance "INFECTIONS in an Urbanizing World - Humans, Animals, Environments" on the control, prevention and control of infectious diseases is coordinated by the FZB and funded by the Leibniz Association under the funding line "Strategic Networking". The interdisciplinary consortium includes 18 Leibniz Institutes from four sections, of which 15 institutes are full members and three institutes are associate members, as well as three external partners.
INFECTIONS builds on the established structures of interdisciplinary research culture and communication of the predecessor consortium INFECTIONS'21 in order to be able to quickly address new challenges posed by infectious diseases across disciplinary boundaries. Strategies for early warning systems and risk assessments, also involving the public, are to be developed that can prevent the rapid spread of pathogens and thus improve the management of infectious outbreaks from a One Health perspective in humans and animals.
Leibniz
Collaborative Excellence
DUSTRISK: Health index for dust and associated microbes, 2020-2023
Leibniz Competition
Research Network 'Lung microbiota at the interface between airway epithelia and environment'
Leibniz ScienceCampus Kiel
Leibniz ScienceCampi promote cooperation on an equal footing between Leibniz institutions and universities in the form of thematically-focused, complementary regional partnerships. The objective is to create networks to drive the respective research field and to strengthen the scientific environment for the relevant themes. The networks conduct strategic research, encourage interdisciplinarity in their topics, projects and methods, enhance the visibility of the respective location and hone its research profile.
The Leibniz ScienceCampus „Evolutionary Medicine of the Lung“ (EvoLUNG). EvoLUNG is based on an approved partnership between FZB, Christian-Albrechts-Universität zu Kiel and the Max-Planck-Institute for Evolutionary Biology in Plön. The objectives to be reached are interdisciplinary research to elucidate severe lung diseases by evolution scientific methods followed by the development of new therapies for diseases such as asthma, tuberculosis, mucoviscidosis and COPD.
Leibniz ScienceCampus Hamburg
Leibniz ScienceCampus „Integrative analysis of pathogen-induced compartments“ (InterACt). Partners are the Heinrich-Pette-Institute, the Bernhard-Nocht-Institute, the University of Hamburg, the University Medical Center Eppendorf and the Centre for Structural Systems Biology.
Federal Ministry for Health
- COVIDSeq_Net: SeqMDRTB_NET extended: application of sequencing technology to elucidate SARS-CoV-2 introduction and dispersion in Mozambique in the framework of Corona Global, 2021-2023
- PHIMS-TB: Public health contribution of a nationwide integrated molecular surveillance using tuberculosis as an example, 2020 – 2022
Federal Ministry for Education and Research
- German Research Center for Lung Research - DZL -
- German Center for Infection Research - DZIF -
- Cluster of Excellence 2167 "Precision Medicine in Chronic Inflammation", 2019-2026
- de_NBI_LIFS: The Borstel site of the service unit 'Lipidomics Informatics for Life Sciences' provides software solutions for systematic lipidome comparisons, which can be seamlessly integrated into workflows of lipidomics studies. Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it. , 2019-2023 - PlasmaplusCorona-FZB (PPC): Plasma-based respiratory tract disinfection to reduce SARS-CoV-2 viral load in vitro and in vivo, 2021-2024
- INDICATE-FH: Improving Diagnostics and therapy of food hypersensitivity, 2021-2024
Federal Ministry for Food and Agriculture
- AptaSens: Development of an aptamer-based biosensor for the detection and investigation of allergens and their allergenic potential in food, 2020-2023
German Research Foundation
- GRK 2633 "Defining and Targeting Autoimmune Pre-Disease", 2023-2027
- Graduate School 2501 "Translational Evolutionary Research" (Trans EVO), 2020-2024
- DFG Priority Programme SPP 2225: "EXIT Strategies of Intracellular Pathogens", 2021-2024
- SFB 1557 "Functional plasticity, encoded by cellular membrane networks"
Horizon 2020
- CARE: Common Action against HIV/TB/HCV across the regions of Europe, 2019-2024
- CORVOS: Marie Sklodowska-Curie Joint European PhD: Complement regulation and variations in opportunistic infections, 2020-2023
- DRTB-HDT: Stratified host-directed therapy for drug-resistant tuberculosis: a randomized controlled multi-centre trial, 2020-2023
- ERA4TB: European Regime Accelerator for Tuberculosis, 2020-2025
- MepAnti: Marie Skodowska-Curie Innovative Training Networks: Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti-infectives, 2020-2024
- Unite4TB: Accelerating the development of new treatment regimens for Tuberculosis, 2021-2028
European and Developing Countries Clinical Trials Partnership (EDCTP)
- VITALITY: Vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunpathology: an individually randomised, double-blinded placebo-controlled trial, 2019-2024
- Core-NB: Collision of three global pandemics: the effect of tuberculosis and HIV on the epidemiological, clinical, virological and immunological trajectory of COVID-19 in Botswana and Namibia, 2021-2023
- ClicTB: The purpose of Clic-TB is to identify and validate a new combination TB drug consisting of one or more novel development candidates for transition to definitive late-stage trials. Borstel will further validate biomarkers as novel measures of early bactericidal activity, which will include PET-CT scans of affected patients in South Africa, 2019-2024
- CUT TB: Community and Universal Testing for TB Contacts, 2020-2024
- STooL4TB: Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV, 2020-2024
National Institute of Health (NIH)
- Quantifiable stool based TB PCR to improve diagnostics and treatment, 2019-2023
- Improved understanding of TB transmission by accounting for within-host heterogeneity of M. tuberculosis – a population-based molecular epidemiology study in a high HIV prevalent setting, 2020-2025
Further Cooperations:
- University of Xiamen: Xiamen-Borstel Joint Laboratory of Autoimmunity, Medical College of Xiamen University. Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it. - University of Namibia: Tuberculosis research laboratories and a training curriculum on infectious diseases. Co-financed by the Schleswig-Holstein TB Society. Contact: Prof. Dr. Stefan Niemann; Prof. Dr. Christoph Lange
The Research Center Borstel, Leibniz Lung Center (FZB), the Medical Faculty of the Christian-Albrechts University of Kiel (CAU) and the University Medical Center Schleswig-Holstein (UKSH) have contractually agreed on the future of the "Leibniz Lung Clinic" on the Kiel campus in 2023. In doing so, they want to use the appeal of pneumological and infectious disease patient care to develop the special clinic and basic research into a joint beacon. In the medium term, the cooperation is to cover the entire field of chronic lung diseases and the lung microbiome. One goal is to establish the Leibniz Lung Clinic as the German clinical reference center for tuberculosis on the Kiel campus, as the pneumologically oriented medical clinic was previously at the FZB.
In clinical research, we cooperate with the Leibniz Lung Clinic at the UKSH Campus Kiel and the following surrounding clinics:
- UK Eppendorf, Hamburg: DZIF, CSSB
- Lung Clinic Grosshansdorf: DZL
- UKSH Campus Lübeck: DZL
Leibniz Chairs express a particularly close relationship between an international researcher and a Leibniz institution. They must be of high international reputation and have rendered long-term and special services to the Leibniz Institute.
The FZB is pleased that the Presidential Board of the Leibniz Association has approved the appointment of two Leibniz Chairs.
We are proud to have Prof. Anna Mandalakes and Prof. Thierry Wirth at our side for five years.
Research Center Borstel
Research Center Borstel, Leibniz Lungcenter
Parkallee 1-40, D-23845 Borstel
Tel. +49 4537 / 188-0
Public relation
Britta Weller
Parkallee 1, 23845 Borstel
Tel. +49 537 / 188-2870
Ombudsmen
Prof. Dr. Cordula Stamme
Parkallee 22, D-23845 Borstel
Tel. +49 4537 / 188-5810
Fax. +49 4537 / 188-7402
Deputies
Dr. Michael Wegmann
Parkallee 22, D-23845 Borstel
Tel. +49 4537 / 188-5830
PD Dr. Karoline Gaede
Parkallee 35, D-23845 Borstel
Tel. +49 4537 / 188-7050
Fax +49 4537 / 188-6360
Equal Opportunities Officer
Nina Grohmann
Parkallee 22, 23845 Borstel
Tel. +49 4537 / 188-4640
Works Council
Parkallee 35, D-23845 Borstel
Tel. +49 4537 / 188-3900
Fax +49 4537 / 188-6900
Netcenter
Parkallee 16, 23845 Borstel
Tel. +49 4537 / 188-2040
Fax +49 4537 / 188-7450
Data protection
Privacy policy
Our company attaches great importance to the protection of personal data and respects your desire for privacy. In the following, we inform you about the collection of personal data when using our website. If you have any further questions regarding the handling of your personal data, please contact our data protection officer.
1. Person responsible
The controller within the meaning of the General Data Protection Regulation (GDPR) is the:
Forschungszentrum Borstel, Leibniz Lungenzentrum,
Parkallee 1-40,
23845 Borstel, Germany
2. How to contact the data protection officer
You can contact our data protection officer at
3. Legal basis of our data processing
The processing of personal data can be based on various legal bases. If we need your data to fulfill a contract with you or to answer your inquiries regarding a contract, the legal basis for this data processing is Art. 6 para. 1 sentence 1 lit. b GDPR. If we obtain your consent for certain data processing, the legal basis is Art. 6 para. 1 sentence 1 lit. a GDPR. We carry out some data processing on the basis of our legitimate interest, whereby a balance is always struck between your interests worthy of protection and our legitimate interests. The legal basis for this is Art. 6 para. 1 lit. f GDPR. Insofar as the processing is necessary to fulfill a legal obligation to which we are subject, the legal basis is Art. 6 para. 1 sentence 1 lit. c GDPR.
Below we explain how we process personal data via our website.
3.1 Data processing when accessing the website
If you use the website for information purposes only, i.e. if you do not contact us via the online form or otherwise provide us with information, we collect the following technical information (log file data):
- Operating system of the terminal device with which you visit our website
- Browser (type, version & language settings)
- The amount of data retrieved
- The current IP address of the terminal device with which you visit our website
- Date and time of access
- The URL of the previously visited website (referrer)
- The URL of the (sub)page that you retrieve on the website
- The Internet service provider of the accessing system
The collection of this data is technically necessary in order to display our website to you and to ensure stability and security. We (and our service provider) regularly do not know who is behind an IP address. We do not combine the data listed above with other data.
The legal basis is Art. 6 para. 1 sentence 1 lit. f GDPR. Since the collection of data for the provision of the website and storage in log files is absolutely necessary for the operation of the website and to protect against misuse, our legitimate interest in data processing prevails at this point.
3.2 Contacting us by e-mail or contact form
When you contact us by e-mail or via a contact form, the data you provide (your e-mail address, your name and telephone number if applicable) will be stored by us in order to answer your questions and process your requests. The legal basis in this respect is Art. 6 para. 1 sentence 1 lit. f GDPR. If we request information via our contact form that is not required for contacting you, we have always marked this as optional. We use this information to specify your request and to improve the processing of your request. This information is provided expressly on a voluntary basis and with your consent, Art. 6 para. 1 sentence 1 lit. a GDPR. If this involves information on communication channels (e.g. email address, telephone number), you also consent to us contacting you via this communication channel in order to respond to your request. You can of course revoke this consent at any time for the future.
Your data that we have received in the course of contacting you will be deleted as soon as it is no longer required to achieve the purpose for which it was collected, your request has been fully processed and no further communication with you is necessary or desired by you.
4. Applications
You can apply to our company via our application portal at https://www.fz-borstel.de/de/arbeiten-am-fzb/stellenanzeigen and by e-mail. Please note that unencrypted e-mails are not transmitted with access protection.
Your data will be used to process your application and to decide on the establishment of an employment relationship. The legal basis is § 26 para. 1 i.V.m. para. 8 sentence 2 BDSG. Furthermore, your personal data may be processed if this is necessary to defend against legal claims asserted against us in the application process. The legal basis for this is Art. 6 para. 1 lit. f) GDPR. The legitimate interest in the processing also lies in the stated purposes.
If there is an employment relationship between you and us, we may process the personal data already received from you for the purposes of the employment relationship in accordance with Section 26 (1) BDSG if this is necessary for the performance or termination of the employment relationship or for the exercise or fulfillment of the rights and obligations of the representation of employees' interests arising from a law or a collective agreement, a works or service agreement (collective agreement).
Your application data will not be processed beyond the use described above.
Your personal data will be deleted after completion of the application process after 6 months at the latest, unless deletion conflicts with any other legitimate interests on our part or you have not given us your consent for longer storage. Other legitimate interest in this sense is, for example, a burden of proof in proceedings under the General Equal Treatment Act (AGG).
5. Use of cookies
Cookies are data that are stored on your computer by a website that you visit and enable your browser to be reassigned. Cookies are used to transmit information to the site that sets the cookie. Cookies can store various information, such as your language setting, the duration of your visit to our website or the entries you make there. Cookies cannot execute programs or transfer viruses to your computer. They are used to make the website more user-friendly and effective overall.
5.1 Transient cookies
These cookies are automatically deleted when you close the browser. These include session cookies in particular. These store a so-called session ID, with which various requests from your browser can be assigned to the joint session. This allows your computer to be recognized when you return to our website. The session cookies are deleted when you log out or close the browser.
5.2 Persistent cookies
These cookies are automatically deleted after a specified period, which may vary depending on the cookie. You can delete the cookies in the security settings of your browser at any time.
6. Social plugins
This website uses social plugins from the provider(s)
- Linkedin (Operator: LinkedIn Ireland Unlimited Company, Wilton Place, Dublin 2, Ireland.)
- X formerly Twitter (Operator: X Corp. 1355 Market Street, Suite 900, San Francisco, CA 94103, USA. The entity responsible for handling data subject rights within the EU/EEA is Twitter International Unlimited Company, Attn: Data Protection Officer, One Cumberland Place, Fenian Street, Dublin 2, D02 AX07 Ireland).
- Blue.Sky (Operator: Bluesky, PBLLC, 113 Cherry St # 24821, Seattle Washington 98104-2205, United States.)
- Norden.social (Operator: norden.social e.V., Zum Sebaldsbrücker Bahnhof 1, 28309 Bremen).
- Instagram (Operator: Meta Platforms, Inc., 1601 Willow Road, Menlo Park California 94025, USA. The responsible body for handling data subject rights within the EU/EEA is the Meta Platforms Ireland Ltd. 4 Grand Canal Square Grand Canal Harbour Dublin 2 Ireland).
These plugins normally collect data from you by default and transmit it to the servers of the respective provider. To ensure the protection of your privacy, we have taken technical measures to ensure that your data cannot be collected by the providers of the respective plugin without your consent. When you call up a page on which the plugins are integrated, they are initially deactivated. The plugins are only activated when you click on the respective symbol, thereby giving your consent for your data to be transferred to the respective provider. The legal basis for the use of the plugins is your consent in accordance with Art. 6 para. 1 lit. a) GDPR, § 25 para. 1 TDDDG (German national law).
Once activated, the plugins also collect personal data, such as your IP address, and send it to the servers of the respective provider, where it is stored. In addition, activated social plugins set a cookie with a unique identifier when the relevant website is accessed. This also allows the providers to create profiles about your usage behavior on websites that you have visited. This happens even if you are not a member of the social network of the respective provider. If you are a member of the provider's social network and you are logged in to the social network during your visit to this website, your data and information about your visit to this website may be linked to your profile on the social network. We have no influence on the exact scope of the data collected from you by the respective provider. For more information about the scope, type and purpose of data processing and about rights and settings options to protect your privacy, please refer to the data protection information of the respective social network provider. These are available at the following addresses:
- Linkedin: https://de.linkedin.com/legal/privacy-policy
- X: https://x.com/en/privacy
- BSky: https://bsky.social/about/support/privacy-policy
- Norden.Social: https://norden.social/privacy-policy
- Instagram: https://www.instagram.com/legal/privacy/
7. Cloudflare
For our website we use the services of CloudFlare Inc, 101 Townsend St, San Francisco, CA 94107 USA.
Cloudflare provides what is known as a Content Delivery Network (CDN). This is a network of globally distributed servers that is able to deliver optimized content to website users. This means that large media files in particular can be delivered via a network of locally distributed servers connected via the Internet. This serves the secure and efficient provision of our website and helps to improve performance and stability.
For this purpose, personal data may be processed in Cloudflare's server log files. Cloudflare also collects statistical data about visits to this website. The data collected includes:
- Name of the website accessed
- Retrieved file
- Date and time of retrieval
- Amount of data transferred
- Notification of successful retrieval
- Browser type and version
- the user's operating system
- Referrer URL
- IP address
- Requesting provider
The legal basis for this data processing is our legitimate interest pursuant to Art. 6 para. 1 lit. f GDPR, § 25 para. 2 TDDDG. Our legitimate interest here lies in the smooth and secure operation of our website. You have the right to object to the processing in accordance with Art. 21 GDPR. Whether the objection is successful must be determined as part of a balancing of interests.
Insofar as data is processed outside the EU/EEA, Cloudflare Inc. has certified itself according to the Data Privacy Framework (DPF) program and is listed in the Data Privacy Framework list of the International Trade Administration (ITA). This means that Cloudflare has publicly committed to complying with the DPF obligations and any data transfer to the USA is harmless due to the current adequacy decision of the European Commission of July 10, 2023.
A list of currently certified US companies can be found here: https://www.dataprivacyframework.gov/s/participant-search. More information on the Data Privacy Framework Program can be found on the official website of the ITA: https://www.dataprivacyframework.gov/s/.
Cloudflare uses the log data for statistical evaluations for the purpose of operation, security and optimization of its own offer. Further information on data processing by Cloudflare, in particular on data protection and data security, can be found at: https://www.cloudflare.com/de-de/privacypolicy/.
8. Newsletter
You can subscribe to our newsletter on our website, which we use to inform you about the latest news, offers and discounts. The legal basis for sending the respective newsletter is your consent in accordance with Art. 6 para. 1 lit. a) GDPR in conjunction with Section 7 para. 2 no. 3 UWG. § Section 7 para. 2 no. 3 UWG or the legal permission according to Section 7 para. 3 UWG.
We use the so-called double opt-in procedure to subscribe to our newsletters. This means that after you have registered, we will send you an e-mail to the e-mail address you have provided in which we ask you to confirm that you wish to receive the newsletter. If you do not confirm your registration, your information will be automatically deleted after 3 days.
The information received will be used to address you personally. After your confirmation, we store your e-mail address for the purpose of sending you the newsletter and until you cancel your subscription. We also store your current IP address at the time of registration, the time of registration and the confirmation for up to three years after registration (limitation period). The purpose of this procedure is to be able to prove your registration in case of doubt and, if necessary, to clarify any misuse of your personal data. The legal basis for logging the registration is our legitimate interest pursuant to Art. 6 para. 1 lit. f) GDPR in providing proof of consent previously given, see also Art. 7 para. 1 GDPR.
You can revoke your consent to the sending of the newsletter at any time and unsubscribe from the newsletter. You can declare your revocation by clicking on the link provided in every newsletter e-mail.
9. Newsletter Tracking
We use rapidmail (rapidmail GmbH, Wentzingerstraße 21, 79106 Freiburg, Germany) to send newsletters. We use rapidmail to organize and analyse the sending of newsletters. The data you enter for the purpose of subscribing to the newsletter is stored on rapidmail's servers in Germany. If you do not wish to be analyzed by rapidmail, you must unsubscribe from the newsletter. For this purpose, we provide a corresponding link in every newsletter message. For the purpose of analysis, the emails sent with rapidmail contain a so-called tracking pixel, which connects to the rapidmail servers when the email is opened. In this way, it can be determined whether a newsletter message has been opened. We can also use rapidmail to determine whether and which links in the newsletter message have been clicked on. Optionally, links in the email can be set as tracking links with which your clicks can be counted.
The legal basis for data processing is Art. 6 para. 1 lit. a) GDPR.
The data will not be transferred to third countries.
The data stored by us as part of your consent for the purpose of the newsletter will be stored by us until you unsubscribe from the newsletter and deleted from both our servers and the servers of rapidmail after you unsubscribe from the newsletter.
You have the option to revoke your consent to data processing at any time with effect for the future. The legality of the data processing operations that have already taken place remains unaffected by the revocation.
For more information, please refer to rapidmail's data security information at: https://www.rapidmail.de/datensicherheit.
For more information on rapidmail's analysis functions, please see the following link: https://www.rapidmail.de/wissen-und-hilfe
10. Data transmission
Your data will not be transferred to third parties except in the cases mentioned, unless we are legally obliged to do so, or the transfer of data is necessary for the execution of the contractual relationship or you have previously expressly consented to the transfer of your data.
External service providers and partner companies such as online payment providers or the shipping company commissioned with the delivery will only receive your data if this is necessary to process your order. In these cases, however, the scope of the transmitted data is limited to the necessary minimum. Insofar as our service providers come into contact with your personal data, we ensure that they comply with the provisions of the data protection laws in the same way as part of order processing in accordance with Art. 28 GDPR. Please also note the respective data protection notices of the providers. The respective service provider is responsible for the content of external services, whereby we check the services for compliance with the legal requirements within the scope of reasonableness.
We attach great importance to processing your data within the EU/EEA. However, we may use service providers who process data outside the EU/EEA. In these cases, we ensure that an adequate level of data protection comparable to the standards within the EU is established at the recipient before your personal data is transferred.
11. Data security
We have taken extensive technical and operational precautions to protect your data from accidental or intentional manipulation, loss, destruction or access by unauthorized persons. Our security procedures are regularly reviewed and adapted to technological progress.
12. Your rights
You have the following rights vis-à-vis us with regard to your personal data. To exercise the above rights, please contact us by email at
Forschungszentrum Borstel, Leibniz Lungenzentrum
Datenschutz-Management
Parkallee 2, 23845 Borstel
Germany
12.1 General rights
We will be happy to provide you with information as to whether personal data concerning you is being processed; if this is the case, you have a right to information about this personal data and to the information listed in detail in Art. 15 GDPR. In addition, you have the right to rectification (Art. 16 GDPR), the right to restriction of processing (Art. 18 GDPR), the right to erasure (Art. 17 GDPR) and the right to data portability (Art. 20 GDPR) under the respective legal requirements.
Without prejudice to any other administrative or judicial remedy, you have the right to lodge a complaint with a supervisory authority, in particular in the Member State of your habitual residence, place of work or place of the alleged infringement if you consider that the processing of personal data relating to you infringes the GDPR. The supervisory authority with which the complaint has been lodged shall inform the complainant on the progress and the outcome of the complaint including the possibility of a judicial remedy pursuant to Art. 78 GDPR.
12.2 Rights in data processing according to the legitimate interest
Pursuant to Art. 21 para. 1 GDPR, you have the right to object at any time, on grounds relating to your particular situation, to the processing of personal data concerning you which is based on Art. 6 para. 1 sentence 1 lit. e GDPR (data processing in the public interest) or on Art. 6 para. 1 sentence 1 lit. f GDPR (data processing to safeguard a legitimate interest). If you object, we will no longer process your personal data unless we can demonstrate compelling legitimate grounds for the processing which override your interests, rights and freedoms, or the processing serves the establishment, exercise or defense of legal claims.
Imprint
Research Center Borstel
Leibniz Lung Center
Parkallee 1-40
D-23845 Borstel
Tel +49 4537 / 188-0
Fax +49 4537 / 188-6030
www.fz-borstel.de
The Research Center Borstel is a foundation under civil law
Representative:
Prof. Dr. Ulrich E. Schaible (Executive Director)
Prof. Dr. Susanne Krauss-Etschmann (Program Director)
Prof. Dr. Dr. h. c. Christoph Lange (Medical Director)
Prof. Dr. Stefan Niemann (Program Director)
Value added tax identification number:
DE 134859311
Supervisory authorities
Ministerium für Inneres, Kommunales, Wohnen und Sport (MIKWS)
Stiftungsaufsicht
Düsternbrooker Weg 92
24105 Kiel
Ministerium für Allgemeine und Berufliche Bildung, Wissenschaft, Forschung und Kultur (MBWFK)
Jensendamm 5
24103 Kiel
Redaktion:
Britta Weller
Forschungszentrum Borstel, Leibniz Lungenzentrum (FZB)
Parkallee 1
23845 Borstel
Layout and Online-Realisation:
Katrin Toedter
Forschungszentrum Borstel, Leibniz Lungenzentrum (FZB)
Parkallee 1
23845 Borstel